The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | PHE885, a novel BCMA-directed CAR-T therapy for patients with R/R multiple myeloma
Adam Sperling, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, explains how the PHE885 CAR-T construct differs from existing BCMA-directed CAR-T therapies and highlights the results of a Phase I trial evaluating this product at different dose levels (NCT04318327). Overall, the study reported early evidence of promising activity and expansion of the CAR-Ts in patients with relapsed/refractory (R/R) multiple myeloma. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
